日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Simian immunodeficiency virus Protein Rev (rev) CSB-YP320111SGX
CSB-EP320111SGX
CSB-BP320111SGX
CSB-MP320111SGX
CSB-EP320111SGX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Human immunodeficiency virus type 1 group M subtype B Truncated surface protein (env) CSB-YP320112HKY
CSB-EP320112HKY
CSB-BP320112HKY
CSB-MP320112HKY
CSB-EP320112HKY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Simian immunodeficiency virus agm.vervet Pol polyprotein (pol) CSB-YP320113SHL
CSB-EP320113SHL
CSB-BP320113SHL
CSB-MP320113SHL
CSB-EP320113SHL-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Human immunodeficiency virus type 1 group M subtype B Virion infectivity factor (vif) CSB-YP320114HKY
CSB-EP320114HKY
CSB-BP320114HKY
CSB-MP320114HKY
CSB-EP320114HKY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Human immunodeficiency virus type 1 group M subtype D Protein Tat CSB-YP320115HLK
CSB-EP320115HLK
CSB-BP320115HLK
CSB-MP320115HLK
CSB-EP320115HLK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Human immunodeficiency virus type 1 group M subtype D Protein Vpu (vpu), partial CSB-YP320116HLK
CSB-EP320116HLK
CSB-BP320116HLK
CSB-MP320116HLK
CSB-EP320116HLK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Human immunodeficiency virus type 1 group M subtype B Protein Vpu (vpu), partial CSB-YP320117HLB
CSB-EP320117HLB
CSB-BP320117HLB
CSB-MP320117HLB
CSB-EP320117HLB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Murine adenovirus A serotype 1 Early E1A 21 kDa protein CSB-YP320118MUS
CSB-EP320118MUS
CSB-BP320118MUS
CSB-MP320118MUS
CSB-EP320118MUS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Human adenovirus A serotype 12 Maturation protein (PIVA2) CSB-YP320119HIB
CSB-EP320119HIB
CSB-BP320119HIB
CSB-MP320119HIB
CSB-EP320119HIB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Human adenovirus A serotype 12 DNA terminal protein (PTP), partial CSB-YP320120HIB
CSB-EP320120HIB
CSB-BP320120HIB
CSB-MP320120HIB
CSB-EP320120HIB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus oryzae Alkaline protease 1 (alp1) CSB-YP320121DPA
CSB-EP320121DPA
CSB-BP320121DPA
CSB-MP320121DPA
CSB-EP320121DPA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Enterobacteria phage P4 Uncharacterized protein ORF88 CSB-YP320122EDH
CSB-EP320122EDH
CSB-BP320122EDH
CSB-MP320122EDH
CSB-EP320122EDH-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Newcastle disease virus Hemagglutinin-neuraminidase (HN), partial CSB-YP320123NCZ1
CSB-EP320123NCZ1
CSB-BP320123NCZ1
CSB-MP320123NCZ1
CSB-EP320123NCZ1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Human parainfluenza 3 virus Hemagglutinin-neuraminidase (HN), partial CSB-YP320124HPF1
CSB-EP320124HPF1
CSB-BP320124HPF1
CSB-MP320124HPF1
CSB-EP320124HPF1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Human respiratory syncytial virus A Fusion glycoprotein F0 (F), partial CSB-YP320125HPP
CSB-EP320125HPP
CSB-BP320125HPP
CSB-MP320125HPP
CSB-EP320125HPP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Newcastle disease virus Fusion glycoprotein F0 (F), partial CSB-YP320126NCQ
CSB-EP320126NCQ
CSB-BP320126NCQ
CSB-MP320126NCQ
CSB-EP320126NCQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Influenza A virus Hemagglutinin (HA), partial CSB-YP320127IBK
CSB-EP320127IBK
CSB-BP320127IBK
CSB-MP320127IBK
CSB-EP320127IBK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Influenza A virus Hemagglutinin (HA), partial CSB-YP320128IFM
CSB-EP320128IFM
CSB-BP320128IFM
CSB-MP320128IFM
CSB-EP320128IFM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Influenza B virus Non-structural protein 1 (NS) CSB-YP320129IJH
CSB-EP320129IJH
CSB-BP320129IJH
CSB-MP320129IJH
CSB-EP320129IJH-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Influenza B virus Non-structural protein 1 (NS) CSB-YP320130IJS
CSB-EP320130IJS
CSB-BP320130IJS
CSB-MP320130IJS
CSB-EP320130IJS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.bdspa.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>



×